Table 3 Summary of findings for minor adverse events: adenosine/atp versus calcium channel antagonists for supraventricular tachycardia
Outcome or subgroup title | Number of studies | Number of participants | Statistical method | Effect size |
|---|---|---|---|---|
Primary outcome | Â | Â | Â | Â |
Odds of reversion | 10 | 960 | Odds Ratio (M-H, Fixed, 95% CI) | 1.44 [0.89, 2.34] |
Major adverse events: Hypotension | 5 | 438 | Odds Ratio (M-H, Fixed, 95% CI) | 3.07 [0.47, 19.85] |
Secondary outcome | Â | Â | Â | Â |
Time to reversion (seconds) | 6 | 574 | Mean Difference (IV, Random, 95% CI) | 423.24 [293.54, 552.93] |
Relapse to SVT post reversion | 4 | 358 | Odds Ratio (M-H, Fixed, 95% CI) | 0.38 [0.09, 1.69] |
Minor adverse events: Chest tightness | 5 | 354 | Odds Ratio (M-H, Fixed, 95% CI) | 0.16 [0.05, 0.56] |
Minor adverse events: Shortness of breath | 3 | 222 | Odds Ratio (M-H, Fixed, 95% CI) | 0.33 [0.08, 1.40] |
Minor adverse events: Flushing | 1 | 50 | Odds Ratio (M-H, Fixed, 95% CI) | 0.01 [0.00, 0.24] |